Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

3 Healthcare Stocks Trading at Attractive Multiples: The Cooper Companies, Inc. (COO), Albany Molecular Research, Inc. (AMRI), Cambrex Corporation (CBM)

Page 1 of 2

Healthcare stocks, in general, have had a nice rally recently, with many shares outperforming the S&P 500 Index.  Despite the rally, some stocks in this sector are still attractively priced.  Three that caught my eye also have good growth prospects.

The healthcare sector is broad and covers a wide range of industries, including medical equipment, pharmaceuticals, and biotech.  That aspect is important to keep in mind, particularly when examining Albany Molecular Research, Inc. (NASDAQ:AMRI), which works with hundreds of pharmaceutical, biotech, and agribusiness customers to conduct research and develop new products, while also providing materials needed for large scale manufacturing of existing products.

The Cooper Companies, Inc.The company’s revenue climbed 9.2% in the trailing-12-month (TTM) period, accelerating from its five-year average.  Similarly, the company has seen its profit margins improve recently.  Its operating margin, for example, widened to 6.7%, from a five-year average of 1.7%.  Better profit margins and faster revenue growth have also translated into EPS improvement.

Shares have climbed about 30% over the last month, easily outpacing the 2% advance in the S&P 500 Index.  Still, the company has solid business prospects for further gains down the road and the stock is attractively priced.  It has a price/sales ratio of 1.1, which is a considerable discount to the average for the industry.  Based on next year’s expected earnings, shares have a P/E ratio of 14.7, further suggesting that they are worth consideration by value-oriented investors.

Cambrex Corporation (NYSE:CBM) provides products and services that help pharmaceutical companies discover and commercialize new human therapeutics, focusing on such areas as cardiovascular, endocrine, and respiratory health, as well as pain management.  Revenue has been climbing nicely.  Net sales advanced 9% in the TTM period, which is a marked improvement from the company’s five-year average of 1.8%.  Also noteworthy is the improvement in profit margins.  Its operating margin widened to 12.9%, from a five-year average of 10.6%, thanks at least partially to higher volume sales.  Cambrex appears well positioned for continued gains this year; management expects top-line growth of about 10%.  A recently penned deal with Dow Chemical (NYSE:DOW) should further help performance going forward.

Cambrex Corporation (NYSE:CBM) shares have climbed about 6% over the last month, but, with a reading of 1.3, they are still priced at a discount to the industry average on the basis of price/sales.  Using next year’s expected earnings, Cambrex Corporation (NYSE:CBM) has a P/E ratio of 11.9, also suggesting that value hunters looking for exposure to healthcare stocks should take a look here.

The Cooper Companies, Inc. (NYSE:COO) is a medical-device company that operates through two divisions.  CooperVision is a key player in the world of soft contact lenses.  CooperSurgical, by comparison, manufactures medical equipment for women’s health, such as in-vitro fertilization (IVF).  Company-wide sales have been relatively consistent.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!